Ursula Bonifas

In vitro determination of tetanus toxicity by an endopeptidase assay linked to a ganglioside-binding step.

Assays for the detection of tetanus neurotoxin (TeNT) are relevant for research applications as well as for the safety testing of tetanus vaccines. So far, these assays are usually performed as toxicity tests in guinea pigs or mice. The alternative methods described to date were mostly based on the detection of the toxins proteolytic activity. However, these endopeptidase assays turned out to be unreliable because they only measure the enzymatic activity as sole determinant of tetanus toxicity, while not taking into account other parameters like the toxins capacity to bind to target cells. In order to better reflect the in vivo situation of a tetanus infection, we have linked an endopeptidase assay to a ganglioside-binding step. The resulting method, which offers a unique combination of two functionally linked assays, detects those TeNT molecules only which possess both a functional binding domain as well as an active enzymatic domain. Our results demonstrate that this assay is able to reliably detect TeNT, and therefore might provide a basis for the replacement of the animal tests for detection of tetanus toxicity. Moreover, the assay concept could also be useful for in vitro toxicity measurements of other toxins with similar subunit structures.

Residual enzymatic activity of the tetanus toxin light chain present in tetanus toxoid batches used for vaccine production

The light chain of tetanus neurotoxin (TeNT) is a zinc-dependent metalloprotease which specifically cleaves the synaptic vesicle protein synaptobrevin. This crucial mechanism of tetanus toxicity leads to a blockade of inhibitory neurotransmitter release. We recently reported the development of a highly sensitive endopeptidase assay for the specific in vitro detection of active TeNT based on this proteolytic feature. Using this method, we could show that formaldehyde-inactivated TeNT preparations (toxoids), which are used for the production of tetanus vaccines, contain a high residual synaptobrevin-cleaving activity. Such an activity was detected in numerous tetanus toxoid batches obtained from several vaccine manufacturers which did not display any in vivo toxicity in the obligatory animal tests. The enzymatic activity could be attributed to the presence of free TeNT light chains whose function had not been restrained by the formaldehyde treatment, but which lack the functional heavy chain necessary for entering neurons in vivo. To our knowledge, this is the first report describing a residual proteolytic activity in tetanus toxoids.

In vitro potency determination of botulinum neurotoxin B based on its receptor-binding and proteolytic characteristics.

Botulinum neurotoxins (BoNTs) are the most potent toxins known. However, the paralytic effect caused by BoNT serotypes A and B is taken advantage of to treat different forms of dystonia and in cosmetic procedures. Due to the increasing areas of application, the demand for BoNTs A and B is rising steadily. Because of the high toxicity, it is mandatory to precisely determine the potency of every produced BoNT batch, which is usually accomplished by performing toxicity testing (LD50 test) in mice. Here we describe an alternative in vitro assay for the potency determination of the BoNT serotype B. In this assay, the toxin is first bound to its specific receptor molecules. After the proteolytic subunit of the toxin has been released and activated by chemical reduction, it is exposed to synaptobrevin, its substrate protein. Finally the proteolytic cleavage is quantified by an antibody-mediated detection of the neoepitope, reaching a detection limit below 0.1mouseLD50/ml. Thus, the assay, named BoNT/B binding and cleavage assay (BoNT/B BINACLE), takes into account the binding as well as the protease function of the toxin, thereby measuring its biological activity.